04-15-02 9P 1644

Docket No.: 237.00

BEFORE THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: SCHEIFLINGER, et al.

Application No.: 09/661,992

Filing Date: September 14, 2000

For: FACTOR IX/FACTOR IXa ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES

Group Art Unit: 1644

Examiner: Decloux, Amy M.

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO OFFICE COMMUNICATION REGARDING SEQUENCE LISTING

In response to the office communication mailed December 12, 2001, the applicant is submitting the following in order to comply with requirements of 37 CFR §§ 1.821 through 1.825:

Sequence Listing

Computer readable diskette containing sequence listing

Statement that "sequence listing" and computer readable copy are the same

Copy of Notice to Comply

Petition for three-months extension of time

Respectfully submitted,

Michael F. Fedrick
Registration No. 36,799
Telephone: (818) 550-4569
Facsimile: (818) 550-4567

BAXTER HEALTHCARE CORPORATION
Post Office Box 15210
Irvine, CA 92623-5210

CERTIFICATE OF MAILING

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail Label EL800475096US in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on April 12, 200

By: Diane Branham
Diane Branham

Docket No.: [illegible]237.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SCHEIFLINGER, et al.

Application No.: 09/661,992

Filed: September 14, 2000

For: FACTORIX/FACTOR IXa ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES

Group Art Unit: 1644

Examiner: Decloux, Amy M.

Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME

I hereby state:

A. The sequence listing information in computer readable form submitted with this application is identical to the written (paper copy) sequence listing submitted herewith.

B. All papers accompanying this submission introduce no new matter.

Respectfully submitted,

Date: April 12, 2002

Michael F. Fedrick, Reg. No. 36,799

Baxter Healthcare Corporation
Post Office Box 15210
Irvine, Ca 92623-5210
Phone 818-550-4569
Fax: 818 550-4567

Application No.: 09/661,992

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☒ 7. Other: See attached communication.

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support (SIRA)
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE